In Russia, the drug «MIR-19», intended for outpatient treatment of coronavirus, will appear
CrimeaPRESS reports:
The Federal Medical and Biological Agency (FMBA) 21 filed an application with the Ministry of Health of the Russian Federation for registration of the drug against coronavirus «MIR-19» for outpatient treatment. The FMBA announced this on Friday, 21 January, on its .
The Federal Medical and Biological Agency has submitted a dossier to the Ministry of Health of Russia for permission for a post-registration clinical trial of a drug for the treatment of a new coronavirus infection «MIR-19» for medical use in outpatient care in the first days after the confirmation of the diagnosis of a new coronavirus infection (COVID-), — the press service of the agency notes.
On behalf of the head of the FMBA, Veronika Skvortsova, the Institute of Immunology of the agency has developed the etiotropic highly specific antiviral drug WORLD-19,” the department specified.
Work on the creation of «MIR-19» was carried out under the guidance of Corresponding Member of the Russian Academy of Sciences Professor Musa Khaitov. The name of the drug stands for «Small Interfering RNA».
As Khaitov explained, the main components of the drug are synthetic molecules of small interfering RNA (siRNA), which, inside the infected cell of the body, target the pathogen genome and contribute to its degradation.
In the course of clinical studies, the safety and effectiveness of «MIR-19» have been proven. When studying the effectiveness, it was studied in a hospital in the «red zone» in patients with moderate severity of COVID-19, the FMBA reported.
The drug is intended for inhalation use. It is administered by inhalation using medical nebulizers.
Comments are closed.